Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.

Qingnan ZhaoJiemiao HuAbhisek MitraJeffry CutreraWendong ZhangZhongting ZhangJun YanXueqing XiaKris Michael MahadeoJohn Andrew LivingstonRichard GorlickShulin Li

Published in: Journal for immunotherapy of cancer (2019)

ttIL-12 when combined with surgery led to conversion to the IFNγHiCD8HiFOXP3LowCD33Low immune profile, eliminated relapse and metastasis, and prolonged overall survival.

Keyphrases

free survival
minimally invasive
immune response
coronary artery bypass
dendritic cells
drug delivery
coronary artery disease
acute coronary syndrome